Hitachi and ADAC partner to hawk PET
Hitachi Medical will be the exclusive distributor of ADAC Laboratories’ PET systems in Japan, the companies announced late last month. The distribution arrangement expands upon an agreement between ADAC and Hitachi that was struck last
Hitachi Medical will be the exclusive distributor of ADAC Laboratories PET systems in Japan, the companies announced late last month. The distribution arrangement expands upon an agreement between ADAC and Hitachi that was struck last year.
The vendors also announced that Hyogo Radiotherapy Center, a cancer treatment facility in Tokyo, has ordered a C-PET system from ADACthe first PET scanner the Milpitas, CA-based company has sold to Japan.
Hitachi markets ADACs Pinnacle3 radiation therapy planning system and its nuclear medicine products, including the Forte dual head gamma camera, molecular coincidence detection with attenuation correction, and Vantage ExSPECT. Hitachi also installs and services ADAC equipment for customers in Japan. Mohamed Elmandjra, ADACs vice president of marketing, said the Japanese PET market is poised to grow after PET scans are approved for insurance reimbursement in that country, which ADAC expects this to happen later this year.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
